{"id":361977,"date":"2010-02-25T10:40:44","date_gmt":"2010-02-25T15:40:44","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=65164"},"modified":"2010-02-25T10:40:44","modified_gmt":"2010-02-25T15:40:44","slug":"trius-sets-ipo-price-range","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/361977","title":{"rendered":"Trius Sets IPO Price Range"},"content":{"rendered":"\n
Biotech<\/a>, Finances<\/a>, deals<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

San Diego-based Trius Therapeutics hopes to sell 6 million shares to investors at a range of $12 to $14 apiece, according to an updated IPO prospectus<\/a> filed with the Securities & Exchange Commission. The company, a developer of new antibiotics, is scheduled to attempt its IPO the week of March 15, according to a calendar<\/a> from Renaissance Capital. If the deal is completed, Trius plans to trade under the ticker “TSRX.” The major stockholders who stand to gain are Sofinnova Ventures, InterWest Partners, Versant Ventures, Prism Venture Partners, and Kleiner Perkins Caufield & Byers.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, Finances, deals Luke Timmerman wrote: San Diego-based Trius Therapeutics hopes to sell 6 million shares to investors at a range of $12 to $14 apiece, according to an updated IPO prospectus filed with the Securities & Exchange Commission. The company, a developer of new antibiotics, is scheduled to attempt its IPO the week of […]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-361977","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/361977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=361977"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/361977\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=361977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=361977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=361977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}